JKHY experienced explosive revenue growth of 299% to $1.5B alongside a dramatic 532% surge in interest expense and a 76% decline in cash position.
The massive revenue increase suggests either a major acquisition, significant organic growth acceleration, or accounting methodology change that requires immediate investigation. The concurrent explosion in interest expense indicates substantial new debt financing, while the sharp cash decline raises questions about capital allocation and liquidity management during this apparent expansion phase.
JKHY's financials show extraordinary growth with revenue surging 299% to $1.5B and gross profit jumping 316% to $612M, indicating either transformational M&A activity or a fundamental business shift. However, interest expense exploded 532% to $15.1M and cash plummeted 76% to $51M, suggesting heavy debt financing and potential liquidity concerns. Despite the revenue explosion, net income grew only modestly at 19%, indicating either integration costs, one-time charges, or margin compression that investors should scrutinize carefully.
Interest expense surged 532.3% — significant debt increase or rising rates materially impacting earnings.
Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.
Strong top-line growth of 299.4% — accelerating demand or successful expansion into new markets.
Cash declined 76.1% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Share repurchases increased 24.9% — management returning capital, signals confidence in intrinsic value.
Net income grew 19.4% — bottom-line growth signals improving overall business health.
Operating income improving — cost discipline or growing revenue base absorbing fixed costs.
Equity base grew 15.7% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Liabilities reduced 15.6% — deleveraging improves balance sheet strength and financial flexibility.
Current liabilities reduced — improved short-term financial position and working capital health.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →